TG Therapeutics Inc: Business Overview, Financials & Competitive Analysis
TG Therapeutics Inc scores 7/10 on the AskCyborg Cyborg Score (Strong). Commercial-stage biotech with blockbuster-potential lead therapy executing strong revenue growth supported by multiple pipeline catalysts through 2027. TG Therapeutics reported full year 2025 revenue of approximately $616 million, with BRIUMVI U.S. net product revenue of $594 million. The company targets $875–900 million in total global revenue for 2026, including.
What is TG Therapeutics Inc's industry? TG Therapeutics Inc (tgtherapeutics.com) operates in Biopharmaceutical / Oncology & Immunology. AskCyborg classifies TG Therapeutics Inc under Biopharmaceutical / Oncology & Immunology in its company registry.
TG Therapeutics is a fully integrated, commercial-stage, biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell diseases. The company has received FDA a...
Cyborg Score thesis
Commercial-stage biotech with blockbuster-potential lead therapy executing strong revenue growth supported by multiple pipeline...
Read the full analyst-debate transcript →Get the Latest TG Therapeutics Inc Report
Up-to-date AI-powered research, analyst debate audio & saved-company playlists
Get Current Report FreeTG Therapeutics Inc Overview
Pro stress-test →TG Therapeutics is a fully integrated, commercial-stage, biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell diseases. The company has received FDA approval for BRIUMVI (ublituximab-xiiy) for adult patients with relapsing forms of multiple sclerosis. With 2025 revenue of $616M and ambitious 2026 guidance of $875-900M, TG Therapeutics is executing aggressive commercial expansion.
Strategic Profile
Pro stress-test →The company generates a majority of its revenue selling BRIUMVI in the United States, with the rest coming from sales in other countries. In development are TG-1701 (BTK inhibitor), Azer-Cel (allogeneic CD19 CAR T), and TG-1801 (anti-CD47/CD19 bispecific mAb) for B-cell disorders, under Phase 1 trials. The company is uniquely positioned to capture market share in B-cell diseases with a commercial-stage asset driving near-term revenue growth.
Competitive Landscape
Pro stress-test →TG Therapeutics has 24 competitors, with Aytu Biopharma listed as one competitor. The company competes in the B-cell disease space with monoclonal antibodies and cell therapies. Key competitive dynamics include multiple sclerosis market positioning against other anti-CD20 agents and pipeline therapies (BTK inhibitors, CAR-T cells) across broader hematologic malignancy markets.
Industry Context
TG Therapeutics Inc operates in Biopharmaceutical / Oncology & Immunology.
Key facts
Founded: 1993 · Headquarters: Morrisville, US · Revenue: $616M · Market cap: $4.52B